← Back to Patent Explorer
US4107315A Expired / Lapsed US ⏱️ 0.0 years remaining

5-(Pyridinyl)-2(1H)-pyridinones

Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1977-07-25
•
Granted: 1978-08-15
•
Expires: 1997-07-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting α-PY-β-(R 1 R 2 N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or α-PY-malonaldehyde (II') with α-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotinic acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Id to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown.

Inventors

  • 👤 George Y. Lesher
  • 👤 Chester J. Opalka, Jr.

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 00:58
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/44; C07D213/53; C07D213/36; C07D213/38; C07D213/46; C07D213/48; C07D213/60; C07D213/62; C07D213/63; C07D213/64; C07D213/72; C07D213/73; C07D213/74; C07D213/75; C07D213/78; C07D213/79; C07D213/80; C07D213/81; C07D213/82; C07D213/84; C07D213/85

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 46 words
A 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula: ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower hydroxy alkyl and Q is hydrogen or halo or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 2
Dependent Claim 46 words
A 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula: ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower hydroxy alkyl and Q is hydrogen or halo or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 3
Dependent Claim 13 words
A compound according to claim 1 where R and Q are each hydrogen.
Claim 4
Dependent Claim 14 words
A compound according to claim 1 where Q is halo and R is hydrogen.
Claim 5
Dependent Claim 5 words
5-(4-Pyridinyl)-2(1H)-pyridinone according to claim 2.
Claim 6
Dependent Claim 5 words
3-Chloro-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 3.
Claim 7
Dependent Claim 5 words
3-Bromo-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 3.
Claim 8
Dependent Claim 66 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 9
Dependent Claim 66 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 10
Dependent Claim 12 words
A composition according to claim 7 where the active component is 5-(4-pyridinyl)-2(1H)-pyridinone.
Claim 11
Independent Claim 74 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridone having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 12
Independent Claim 74 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridone having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 13
Dependent Claim 11 words
The method according to claim 9 where the 1-R-3-Q-5-PY-2(1H)-pyridinone is 5-(4-pyridinyl)-2(1H)-pyridinone.
Claim 14
Dependent Claim 34 words
The process of preparing the compound of claim 1 where Q is halo and R is hydrogen which comprises reacting 5-PY-2(1H)-pyridinone with halogen to produce 3-halo-5-PY-2(1H)-pyridinone where PY is defined as in claim 1.
Claim 15
Dependent Claim 29 words
The process for preparing the compounds of claim 1 where Q is hydrogen which comprises reacting the corresponding compound where Q is carboxy or cyano with aqueous mineral acid.
Claim 16
Dependent Claim 20 words
The process according to claim 12 which comprises reacting 1,2-dihydro-2-oxo-5-(4-pyridinyl)-nicotinonitrile or 1,2-dihydro-2-oxo-5-(4-pyridinyl)-nicotinic acid with aqueous sulfuric acid to produce 5-(4-pyridinyl)-2(1H)-pyridinone.
Claim 17
Dependent Claim 41 words
The process for preparing the compound of claim 1 where Q is halo which comprises the steps of heating 1,2-dihydro-2-oxo-5-PY-nicotinonitrile or 1,2-dihydro-2-oxo-5-PY-nicotinic acid with an aqueous mineral acid to produce 5-PY-2(1H)-pyridinone and reacting 5-PY-2(1H)-pyridinone with halogen to produce the corresponding 3-halo-5-PY-2(1H)-pyridinone.
Claim 18
Dependent Claim 50 words
The process which comprises the steps of reacting 1-R-5-PY-2(1H)-pyridinone with halogen to produce the corresponding 1-R-3-halo-5-PY-2(1H)-pyridinone according to claim 1 and reacting said 3-halo compound with a lower-alkylamine or di-(lower-alkyl)amine, to produce the corresponding respective 3-(lower-alkylamino) or 3-[di-(lower-alkyl)amino] compound, where PY and R have the meanings given in claim 1.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-08-14 1982-02-13 1982-08-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-08-14 1986-02-13 1986-08-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-08-14 1990-02-13 1990-08-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag